Business context and reporting period
Filing identity mismatch: The supplied filing is for Deep Medicine Acquisition Corp. (NASDAQ: DMAQ/DMAQR), not TruGolf Holdings, Inc. It is a Form 10-K for the fiscal year ended March 31, 2022, not a 2021 fourth-quarter report.
Deep Medicine was a blank-check company formed to pursue a business combination, with a stated focus on healthcare and digital health/AI in medicine. It had no operating business or revenue as of March 31, 2022, and reported no selected target or substantive target discussions. Its IPO closed October 29, 2021.
Financial results and liquidity
| Metric | Year ended March 31, 2022 | Prior comparable period |
|---|---|---|
| Revenue | None; no operations commenced | None |
| Operating and formation expenses | $409,912 | $59,395, from inception July 8, 2020 to March 31, 2021 |
| Net loss | $414,045 | $59,395 |
| Net cash used in operating activities | $697,868 | $50,033, from inception |
At March 31, 2022, cash outside the trust was $877,099; working capital was $655,693. Trust-account assets were $127,760,867, invested primarily in U.S. Treasury money-market funds. Total assets were $128,953,272 and total liabilities were $4,964,212, including a $500,000 zero-interest sponsor loan and $4,427,500 of deferred underwriting commissions payable only if a business combination closes. Redeemable public shares of $127,765,000 were classified as temporary equity. No operating margins are meaningful because the company had no revenue.
The IPO sold 12.65 million units at $10 each and raised $126.5 million gross; a concurrent private placement raised $5.195 million. Transaction costs were $7.283 million. Compared with the prior inception period, the IPO substantially increased trust assets and cash, while the company began incurring public-company and target-search expenses.
Outlook, risks, contingencies, and unusual items
- The company intended to complete a business combination within 12 months of the IPO, with up to two three-month extensions if the sponsor deposited $1.265 million per extension. No assurance was given that an extension would be funded or a transaction completed.
- The independent auditor’s report contains a going-concern explanatory paragraph and says the liquidation deadline raises substantial doubt about continuing as a going concern. The notes likewise cite substantial doubt due to limited liquidity, ongoing costs, and the lack of committed additional financing. MD&A says the IPO proceeds alleviated the doubt; investors should note this difference in presentation.
- Management reported no material change in financial or trading position and no material adverse change since the audited statements. The filing provides no earnings or operating guidance.
- Key SPAC risks include failure to find or close a target before the deadline; redemptions reducing cash available at closing; dependence on potential additional financing; competition for targets; and potential dilution from founder-share anti-dilution provisions, rights, warrants, and new securities.
- Public shareholders generally could redeem for a pro rata share of trust assets, initially estimated at $10.10 per share, subject to stated conditions. If no combination is completed, public rights expire worthless. Creditor claims, bankruptcy, or negative trust investment returns could reduce distributions; sponsor indemnification is limited and its ability to pay was not assured.
- Potential conflicts include founders’ nominal-cost shares, a 300,000-share post-combination award for officers and directors, the deferred $4.428 million marketing fee, and management’s other business obligations. The filing also discloses related-party payments and a $500,000 sponsor loan.
Important facts for investors to verify
- Confirm the issuer and reporting period: this is Deep Medicine Acquisition Corp.’s FY2022 filing, not a TruGolf filing or a 2021 Q4 report.
- Check subsequent filings for any business-combination agreement, extension funding, redemptions, liquidation, or changes to the trust balance.
- Review the audited financial statements and going-concern disclosures alongside MD&A’s statement that liquidity concerns were alleviated.
- Verify cash available outside the trust, the sponsor loan and repayment terms, deferred underwriting fees, and any further financing or dilution.
- Assess redemption mechanics, creditor-claim exposure, founder incentives, related-party arrangements, and the effect of rights and warrants on post-combination ownership.